GSK lightens portfolio, shrinks footprint

GSK lightens porfolio, shrinks footprint
GSK lightens porfolio, shrinks footprint

GlaxoSmithKline is selling thrombosis meds Arixtra and Fraxiparine to the Aspen Group, a longtime partner in GSK's ongoing effort to transfer drugs from its books to another entity. The company said in a statement Monday that the deal will include $1.3 million in cash and that it transfers global rights, with few exceptions, to the products and to a manufacturing site (the Notre Dame de Bondeville site) and “certain dedicated commercial employees.” GSK said in a statement that the deal “is a further example of GSK's commitment to increase focus on products with the most growth potential.”

You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.